Tofacitinib for the treatment of rheumatoid arthritis

@article{Zerbini2012TofacitinibFT,
  title={Tofacitinib for the treatment of rheumatoid arthritis},
  author={Cristiano A F Zerbini and Andrea Barranjard Vannucci Lomonte},
  journal={Expert Review of Clinical Immunology},
  year={2012},
  volume={8},
  pages={319 - 331}
}
Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects approximately 1% of the worldwide population. It primarily targets the synovial membrane of joints, leading to a synovial proliferation, joint cartilage lesion and erosions in the adjacent bone tissue. The disease is usually progressive and if the inflammatory process is not adequately suppressed, joint deformity takes place, leading to a significant functional disability and work incapacity. Over the last decade… 
A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis
TLDR
Tofacitinib monotherapy, or in combination with traditional DMARDs, has demonstrated its efficacy while having an acceptable safety profile in RA patients who have responded inadequately to current DMARDS, including TNF antagonists.
Advances in the treatment of rheumatoid arthritis
TLDR
Recently, the approval of the first small molecule targeting intracellular pathways has opened a new chapter in the treatment of rheumatoid arthritis and other emerging treatment strategies include the activation of regulatory T cells as well as new cytokine-targeting therapies.
Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
TLDR
Tofacitinib has a noticeable efficacy in controlling disease activity in RA with a manageable safety profile, however, longer studies are needed for its long-term safety profile.
Baricitinib: From Rheumatoid Arthritis to COVID‐19
TLDR
The significant efficacy of baricitinib, versus the probable adverse effects, urge further investigation before establishing it as a part of standard therapeutic protocols.
Pharmacotherapy Options in Rheumatoid Arthritis
TLDR
There is some evidence that tocilizumab is the most effective biologic as a monotherapy agent, but the long term data for the newer oral small molecule biologics such as tofacitinib is not available and hence used only as a last resort.
Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis
TLDR
In a Brazilian subpopulation of patients with RA, tofacitinib reduced disease signs and symptoms and improved physical function up to Month 24, with a safety profile consistent with findings from global studies.
JAK/STAT pathway in pathology of rheumatoid arthritis (Review)
TLDR
A narrative review focuses on the intricate signaling pathways involved as well as on the clinical aspects and safety profiles of JAKinibs approved for the treatment of RA.
Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
TLDR
Tofacitinib is efficacious and well tolerated in patients with MTX-resistant RA up to a period of 24 weeks, however, haematological, liver function tests and lipoproteins should be monitored.
Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
TLDR
Tofacitinib is an oral JAK inhibitor that is now available and effective in RA treatment, as shown in multiple Phase II and Phase III clinical trials, however, long-term safety data and comparisons with other disease-modifying antirheumatic drugs and small molecule inhibitors are necessary to better determine the role of tofacitinIB in RA.
Psoriatic arthritis for the dermatologist.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase
TLDR
Subclinical inflammation of the synovium does not coincide with the appearance of serum autoantibodies during the pre-RA stage, suggesting that a ‘second hit’ is involved and supports the rationale for exploring preventive strategies aimed at interfering with the humoral immune response before synovial inflammation develops.
Evolving concepts of rheumatoid arthritis
TLDR
Based on the pathogenic mechanisms, specific therapeutic interventions can be designed to suppress synovial inflammation and joint destruction in rheumatoid arthritis.
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.
TLDR
Etanercept as monotherapy was safe and was superior to MTX in reducing disease activity, arresting structural damage, and decreasing disability over 2 years in patients with early, aggressive RA.
Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis
TLDR
Animal models with at least partial features of the vasculopathy observed in systemic sclerosis include wound healing models, graft versus host disease models and, in particular, the University of California at Davis line 200 chicken model of systemic sclerosis.
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.
TLDR
Treatment with MRA was generally well tolerated and significantly reduced the disease activity of RA, and the adverse events were not dose dependent.
Tofacitinib (CP-690,550), an oral janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: A 24-Month Phase 3 Study
TLDR
Tofacitinib is a novel, oral JAK inhibitor that is being investigated as a targeted immunomodulator and disease modifying therapy for RA and efficacy and safety shown in Phase 2b monotherapy and background MTX dose-ranging studies.
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
The revised criteria for the classification of rheumatoid arthritis (RA) were formulated from a computerized analysis of 262 contemporary, consecutively studied patients with RA and 262 control
Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort).
TLDR
It is demonstrated for the first time in a prospective study that synovial membrane cytokine mRNA expression is predictive of joint damage progression in RA.
Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis
TLDR
The efficacy observed with CP-690550 in CIA and AA suggests JAK3 inhibition may represent a novel therapeutic target for the treatment of RA.
Cytokine networks—towards new therapies for rheumatoid arthritis
TLDR
Evidence indicates that IL-6 antagonists might represents a useful approach and preliminary data similarly identify IL-15 as an intriguing target, and development of the capacity for cytokine targeting to modify the underlying immune dysregulation remains a major priority.
...
1
2
3
4
5
...